221 related articles for article (PubMed ID: 21361888)
1. Continual reassessment method for partial ordering.
Wages NA; Conaway MR; O'Quigley J
Biometrics; 2011 Dec; 67(4):1555-63. PubMed ID: 21361888
[TBL] [Abstract][Full Text] [Related]
2. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding design for multi-drug combinations.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
[TBL] [Abstract][Full Text] [Related]
4. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
5. Designs for single- or multiple-agent phase I trials.
Conaway MR; Dunbar S; Peddada SD
Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
[TBL] [Abstract][Full Text] [Related]
6. Specifications of a continual reassessment method design for phase I trials of combined drugs.
Wages NA; Conaway MR
Pharm Stat; 2013; 12(4):217-24. PubMed ID: 23729323
[TBL] [Abstract][Full Text] [Related]
7. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
8. Phase I design for completely or partially ordered treatment schedules.
Wages NA; O'Quigley J; Conaway MR
Stat Med; 2014 Feb; 33(4):569-79. PubMed ID: 24114957
[TBL] [Abstract][Full Text] [Related]
9. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
Muenz DG; Braun TM; Taylor JM
Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
[TBL] [Abstract][Full Text] [Related]
10. Sequential designs for phase I clinical trials with late-onset toxicities.
Cheung YK; Chappell R
Biometrics; 2000 Dec; 56(4):1177-82. PubMed ID: 11129476
[TBL] [Abstract][Full Text] [Related]
11. Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.
Patel A; Brock K; Slade D; Gaunt C; Kong A; Mehanna H; Billingham L; Gaunt P
BMC Med Res Methodol; 2024 Jan; 24(1):11. PubMed ID: 38218799
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of dose-finding studies to observation errors.
Zohar S; O'Quigley J
Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
[TBL] [Abstract][Full Text] [Related]
13. The continual reassessment method for dose-finding studies: a tutorial.
Garrett-Mayer E
Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
[TBL] [Abstract][Full Text] [Related]
14. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
Wages NA; Tait C
J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
[TBL] [Abstract][Full Text] [Related]
15. Continual reassessment method with multiple toxicity constraints.
Lee SM; Cheng B; Cheung YK
Biostatistics; 2011 Apr; 12(2):386-98. PubMed ID: 20876664
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
[TBL] [Abstract][Full Text] [Related]
17. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM.
Saha PT; Fine JP; Ivanova A
Stat Med; 2021 Apr; 40(8):2073-2082. PubMed ID: 33588519
[TBL] [Abstract][Full Text] [Related]
18. Curve-free and model-based continual reassessment method designs.
O'Quigley J
Biometrics; 2002 Mar; 58(1):245-9. PubMed ID: 11890323
[TBL] [Abstract][Full Text] [Related]
19. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
20. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]